Cholesterol efflux stimulation in BPDCN cells amplifies LXR activation-induced effects. BPDCN CAL-1 and GEN2.2 cells or primary BPDCN samples were treated with 1 µM LXR agonists T0901317 (T09) or GW3965 (GW) for 24 hours. (A-B) Phospho-STAT5 (Y694) and phospho-Akt (S473) were assessed by confocal microscopy after LXR stimulation, followed by APOA1 (10 µg/mL) addition for 4 hours, and then IL-3 stimulation (10 ng/mL for 30 minutes). (A) Data from 1 representative sample of 2 BPDCN samples (LPDC #5, #8) are shown. (B) Data from 1 representative experiment of 3 for CAL-1 and GEN2.2 cells are shown. (C) CAL-1 cells were treated with 10 µM T0901317 or GW3965 simultaneously to increasing concentrations of APOA1 (5, 10, or 20 µg/mL) for 24 hours. Cell death was assessed by AnxV/7AAD staining analyzed by cytometry. Dot plots from 1 representative experiment of 6 are shown (left panel); only data obtained with GW treatment are depicted. Cumulative data from the 6 independent experiments expressed as mean ± SEM of dead AnxV⁺ cells are shown (right panel, *P < .05, **P < .01, Mann-Whitney).